SCYNEXIS Inc
NASDAQ:SCYX

Watchlist Manager
SCYNEXIS Inc Logo
SCYNEXIS Inc
NASDAQ:SCYX
Watchlist
Price: 0.63 USD -0.08%
Market Cap: 26.4m USD

Operating Margin
SCYNEXIS Inc

-1 181.1%
Current
-825%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 181.1%
=
Operating Profit
-34.6m
/
Revenue
2.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
SCYNEXIS Inc
NASDAQ:SCYX
26.5m USD
-1 181%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
500.1B USD
27%
CH
Roche Holding AG
SIX:ROG
257.6B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
24%
CH
Novartis AG
SIX:NOVN
206.1B CHF
33%
US
Merck & Co Inc
NYSE:MRK
249.9B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
142.3B USD
29%
No Stocks Found

SCYNEXIS Inc
Glance View

Market Cap
26.4m USD
Industry
Pharmaceuticals

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 56 full-time employees. The company went IPO on 2014-05-02. The firm is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. The company has received the approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC). The company is also continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients.

SCYX Intrinsic Value
0.29 USD
Overvaluation 53%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 181.1%
=
Operating Profit
-34.6m
/
Revenue
2.9m
What is the Operating Margin of SCYNEXIS Inc?

Based on SCYNEXIS Inc's most recent financial statements, the company has Operating Margin of -1 181.1%.

Back to Top